AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23328663 — intervention group
Group type: EXPERIMENTAL
Intervention: Human computation (HC) method
Number of subjects: 120
Study 23328663 — intervention group
Group type: COMPARATOR
Intervention: Informal consensus (IC) method
Number of subjects: 120
Study 21699432 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 34
Study 21699432 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 34
Study 21699432 — intervention group
Group type: COMPARATOR
Intervention: Both VCV and PCV
Number of subjects: 34
Study 18504236 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavon Max product
Number of subjects: 0
Study 18504236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16426961 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-enriched beverage
Number of subjects: 268
Study 16426961 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 268
Study 12659385 — intervention group
Group type: COMPARATOR
Intervention: Nebulized albuterol
Number of subjects: 0
Study 12659385 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol plus ipratropium
Number of subjects: 0
Study 11153621 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding solution enriched with vitamins A (67 microg/dL), C (13.3 mg/dL), and E (4.94 mg/dL)
Number of subjects: 51
Study 11153621 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous control solution
Number of subjects: 51
Study 9244718 — intervention group
Group type: EXPERIMENTAL
Intervention: TEPT-guided antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Number of subjects: 160
Study 9244718 — intervention group
Group type: COMPARATOR
Intervention: Empiric antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Number of subjects: 160
Study 9244718 — intervention group
Group type: EXPERIMENTAL
Intervention: TEPT-guided therapy
Number of subjects: 160
Study 1543305 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fitness walking and patient education
Number of subjects: 102
Study 1543305 — intervention group
Group type: COMPARATOR
Intervention: Standard routine medical care
Number of subjects: 102
Study 3897351 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.00 D. add group
Number of subjects: 213
Study 3897351 — intervention group
Group type: EXPERIMENTAL
Intervention: +2.00 D. add group
Number of subjects: 213
Study 3897351 — intervention group
Group type: COMPARATOR
Intervention: Single vision (standard treatment) group
Number of subjects: 213
Study 31892611 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IUs/day of oral vitamin D3
Number of subjects: 20
Study 31892611 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 IUs/day of oral vitamin D3
Number of subjects: 20
Study 31892611 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IUs/day of oral vitamin D3
Number of subjects: 20
Study 29945555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 84
Study 29945555 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 84
Study 27006113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor antagonist (sulpiride 400 mg)
Number of subjects: 44
Study 27006113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27006113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological Gamblers
Number of subjects: 44
Study 27006113 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 44
Study 25015680 — intervention group
Group type: COMPARATOR
Intervention: 0 g of oral tyrosine
Number of subjects: 24
Study 25015680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral tyrosine
Number of subjects: 24
Study 25015680 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of oral tyrosine
Number of subjects: 24
Study 25015680 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of oral tyrosine
Number of subjects: 24
Study 25015680 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma tyrosine
Number of subjects: 24
Study 21990343 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP) for diabetes type 2
Number of subjects: 1489
Study 20187278 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FMD procedures
Number of subjects: 0
Study 20187278 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FMD procedures and acute aerobic exercise
Number of subjects: 0
Study 20187278 — intervention group
Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 0
Study 18753801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma hand massage
Number of subjects: 58
Study 18753801 — intervention group
Group type: COMPARATOR
Intervention: General oil hand massage
Number of subjects: 58
Study 17283929 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarisation with the transparency display (experiment 1)
Number of subjects: 24
Study 17283929 — intervention group
Group type: COMPARATOR
Intervention: Familiarisation with the non-transparent display (experiment 2)
Number of subjects: 24
Study 11810087 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe gestational hypertension (without proteinuria)
Number of subjects: 598
Study 11810087 — intervention group
Group type: COMPARATOR
Intervention: Mild preeclampsia
Number of subjects: 598
Study 11810087 — intervention group
Group type: COMPARATOR
Intervention: Normotensive/mild gestational hypertension
Number of subjects: 598
Study 10808389 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg)
Number of subjects: 10
Study 10808389 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 10
Study 10808389 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg)
Number of subjects: 10
Study 10808389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7596852 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 18
Study 2191592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tetradecyl sulfate
Number of subjects: 0
Study 2191592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate
Number of subjects: 0
Study 2191592 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 0
Study 2191592 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 7210690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (Anxiolit retard)
Number of subjects: 0
Study 7210690 — intervention group
Group type: COMPARATOR
Intervention: No administration of Oxazepam
Number of subjects: 0
Study 28859993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 0
Study 28859993 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (gel)
Number of subjects: 0
Study 28859993 — intervention group
Group type: COMPARATOR
Intervention: Topical ciprofloxacin (other formulations)
Number of subjects: 0
Study 26081567 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa targeting hemoglobin (Hb) levels of 11-13 g/dL
Number of subjects: 498
Study 26081567 — intervention group
Group type: COMPARATOR
Intervention: Low Hb group maintained at 9.0-11.0 g/dL using epoetin alfa
Number of subjects: 498
Study 24614074 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-gastric infusion of chocolate milk (stomach distention + nutrients)
Number of subjects: 14
Study 24614074 — intervention group
Group type: COMPARATOR
Intervention: Naso-gastric infusion of water (stomach distention)
Number of subjects: 14
Study 24614074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of chocolate milk (stomach distention + nutrients + oral exposure)
Number of subjects: 14
Study 22036776 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 99
Study 22036776 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 150 U
Number of subjects: 99
Study 22036776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 20527136 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% formic acid in distilled water solution
Number of subjects: 34
Study 20527136 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 34
Study 16782320 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 177
Study 16782320 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Georges Respiratory Questionnaire (SGRQ)
Number of subjects: 177
Study 16782320 — intervention group
Group type: COMPARATOR
Intervention: Generic measures (SF-36, Feeling Thermometer, Standard Gamble, Health Utilities index 3)
Number of subjects: 177
Study 16272420 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone mode of G-CAHPS survey
Number of subjects: 880
Study 16272420 — intervention group
Group type: COMPARATOR
Intervention: Mail mode of G-CAHPS survey
Number of subjects: 880
Study 11906502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg single dose)
Number of subjects: 226
Study 11906502 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily for 3 days)
Number of subjects: 226
Study 9759984 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 23
Study 9759984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 23
Study 9759984 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily for 3 months)
Number of subjects: 23
Study 9759984 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 23
Study 7799050 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment administered intranasally for five days
Number of subjects: 0
Study 7799050 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 3197372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering one foot 50 cm below heart level
Number of subjects: 102
Study 3197372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic blockade (epidural anaesthesia)
Number of subjects: 102
Study 3197372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering one foot below heart level
Number of subjects: 102
Study 3197372 — intervention group
Group type: EXPERIMENTAL
Intervention: Local nervous blockade (lignocaine 3.7 x 10(‐4)‐7.4 x 10(‐2) mol/l)
Number of subjects: 102
Study 28457980 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP) 15 mL/kg of bodyweight
Number of subjects: 100
Study 28457980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation Factor Concentrates (CFC) primarily fibrinogen concentrate 50 mg/kg of bodyweight
Number of subjects: 100
Study 28457980 — intervention group
Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 100
Study 28457980 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation Factor Concentrates (CFC)
Number of subjects: 100
Study 25481576 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual services plus LVSMP (8-week group programme facilitated by low vision counsellors)
Number of subjects: 153
Study 25481576 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 153
Study 23523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 175
Study 23523131 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 175
Study 23523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine dropouts
Number of subjects: 175
Study 23523131 — intervention group
Group type: COMPARATOR
Intervention: Methadone dropouts
Number of subjects: 175
Study 21263100 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly intravenous dactinomycin 1.25 mg/m²
Number of subjects: 216
Study 21263100 — intervention group
Group type: COMPARATOR
Intervention: Weekly intramuscular (IM) methotrexate 30 mg/m²
Number of subjects: 216
Study 19916640 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotion condition
Number of subjects: 4
Study 19916640 — intervention group
Group type: COMPARATOR
Intervention: Control condition (positive or no emotions)
Number of subjects: 4
Study 16492848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands on the P6 acupoint
Number of subjects: 110
Study 16492848 — intervention group
Group type: COMPARATOR
Intervention: Placebo bands on the P6 acupoint
Number of subjects: 110
Study 15042325 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-desmethoxyfallypride (18F-DMFP) PET imaging after injection of 180-200 MBq
Number of subjects: 51
Study 15042325 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-DMFP PET imaging
Number of subjects: 51
Study 15042325 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 51
Study 11053269 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial spectacle correction
Number of subjects: 148
Study 11053269 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated group
Number of subjects: 148
Study 11053269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no significant refractive errors)
Number of subjects: 148
Study 9126305 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (mean 9,000 mg) preoperatively
Number of subjects: 42
Study 9126305 — intervention group
Group type: COMPARATOR
Intervention: No anticancer agents (Control group B)
Number of subjects: 42
Study 7984719 — intervention group
Group type: EXPERIMENTAL
Intervention: Popping air capsules for 5 minutes (experimental group)
Number of subjects: 0
Study 7984719 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 2720864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 40
Study 2720864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen diet during irradiation
Number of subjects: 15
Study 2995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pollen added to diet)
Number of subjects: 15
Study 31862192 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT twisting technique
Number of subjects: 540
Study 31862192 — intervention group
Group type: COMPARATOR
Intervention: Static ETT technique
Number of subjects: 540
Study 31288829 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER intervention
Number of subjects: 60
Study 31288829 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 60
Study 28434406 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV (abacavir + lamivudine + efavirenz)
Number of subjects: 156
Study 28434406 — intervention group
Group type: COMPARATOR
Intervention: LPV (zidovudine + abacavir + lamivudine + lopinavir/ritonavir)
Number of subjects: 156
Study 24274771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa treatment (37 g/d of dark chocolate and a sugar-free cocoa beverage, total cocoa = 22 g/d, total flavanols = 814 mg/d)
Number of subjects: 30
Study 24274771 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (low-flavanol chocolate bar and a cocoa-free beverage, total flavanols = 3 mg/d)
Number of subjects: 30
Study 24274771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa treatment
Number of subjects: 30
Study 22170713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC; n=20; glucose goal, 80‐140 mg/dl)
Number of subjects: 75
Study 22170713 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glycemic control (CGC; n=20; glucose goal, 180‐200 mg/dl)
Number of subjects: 75
Study 22170713 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK; n=10; glucose goal, 180‐200 mg/dl)
Number of subjects: 75
Study 22170713 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 patients with glycemia below 140 mg/dl)
Number of subjects: 75
Study 20691307 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 6166
Study 20691307 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG only
Number of subjects: 6166
Study 20691307 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) only
Number of subjects: 6166
Study 20691307 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG+PCI
Number of subjects: 6166
Study 20691307 — intervention group
Group type: COMPARATOR
Intervention: Nonrevascularized patients
Number of subjects: 6166
Study 17505990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of famotidine (10 mg) and omeprazole (20 mg)
Number of subjects: 0
Study 17505990 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg)
Number of subjects: 0
Study 17505990 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (10 mg)
Number of subjects: 0
Study 16173416 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM regimen (one-dose regimen)
Number of subjects: 51
Study 16173416 — intervention group
Group type: COMPARATOR
Intervention: PB-MDT regimen (standard regimen)
Number of subjects: 51
Study 12417288 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 325
Study 12417288 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 325
Study 10520779 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg daily for 4 weeks
Number of subjects: 32
Study 10520779 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 32
Study 7712392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 41
Study 7712392 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 41
Study 2502950 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin applied three times daily
Number of subjects: 75
Study 2502950 — intervention group
Group type: COMPARATOR
Intervention: Oral erythromycin ethylsuccinate (30 to 50 mg/kg per day)
Number of subjects: 75
Study 852890 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets
Number of subjects: 470
Study 852890 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets (fasting)
Number of subjects: 470
Study 852890 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg pivampicillin tablets (non-fasting)
Number of subjects: 470
Study 30727810 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine approach to physical therapy (BMPI)
Number of subjects: 12
Study 31424182 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA anodal tDCS over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 10
Study 31424182 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 28849588 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 80
Study 25986004 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention (feedback of analysed audit data)
Number of subjects: 0
Study 25986004 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 0
Study 25986004 — intervention group
Group type: COMPARATOR
Intervention: Control wards
Number of subjects: 0
Study 24195291 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG oligodeoxynucleotide (ODN) stimulation
Number of subjects: 0
Study 21602648 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (TG)
Number of subjects: 49
Study 21602648 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 49
Study 19843481 — intervention group
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 107
Study 19843481 — intervention group
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 107
Study 19843481 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study 19843481 — intervention group
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0% and 1.5%
Number of subjects: 107
Study 16944409 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1203
Study 16944409 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 1203
Study 16944409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1203
Study 16944409 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram vs Citalopram
Number of subjects: 1203
Study 16944409 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI-S and CGI-I
Number of subjects: 1203
Study 15517747 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydropolymer foam dressing (Tielle, Johnson & Johnson)
Number of subjects: 140
Study 11073179 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetic footcare model
Number of subjects: 1939
Study 9293128 — intervention group
Group type: EXPERIMENTAL
Intervention: IOTN learning package used by test group GDPs
Number of subjects: 40
Study 9293128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IOTN learning package)
Number of subjects: 40
Study 9293128 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group GDPs
Number of subjects: 40
Study 8448066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 12
Study 8448066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3298412 — intervention group
Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.
Number of subjects: 8
Study 3298412 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 8
Study 3298412 — intervention group
Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (Wellferon)
Number of subjects: 8
Study 30237705 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance routine + usual care
Number of subjects: 60
Study 30237705 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 60
Study 26912478 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 13
Study 23860273 — intervention group
Group type: EXPERIMENTAL
Intervention: TY-51924 (up to 30 mg/kg)
Number of subjects: 0